

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7122791

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
UNUM THERAPEUTICS INC.	09/21/2020
RECEIVING PARTY DATA	
Name:	SOTIO, LLC
Street Address:	180 CANAL STREET
Internal Address:	3RD FLOOR
City:	BOSTON
State/Country:	MASSACHUSETTS
Postal Code:	02114
PROPERTY NUMBERS Total: 3	
Property Type	Number
Application Number:	17274021
Application Number:	17268345
Application Number:	17291963
CORRESPONDENCE DATA	
Fax Number:	(617)535-3800
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6175353981
Email:	cameyer@mwe.com, IPDocketBoston@mwe.com
Correspondent Name:	MCDERMOTT WILL & EMERY
Address Line 1:	200 CLARENDON STREET
Address Line 2:	58TH FLOOR
Address Line 4:	BOSTON, MASSACHUSETTS 02116-5021
ATTORNEY DOCKET NUMBER:	112309-0072, -0080, -0089
NAME OF SUBMITTER:	CASSANDRA MEYER
SIGNATURE:	/Cassandra Meyer/
DATE SIGNED:	01/14/2022
Total Attachments: 5	
source=20200921_Assignment_Unum_SOTIO#page1.tif	
source=20200921_Assignment_Unum_SOTIO#page2.tif	

source=20200921_Assignment_Unum_SOTIO#page3.tif

source=20200921_Assignment_Unum_SOTIO#page4.tif

source=20200921_Assignment_Unum_SOTIO#page5.tif

PATENT

REEL: 058661 FRAME: 0036

CORPORATE TO CORPORATE ASSIGNMENT

Attorney Docket No.: _____

WHEREAS Unum Therapeutics Inc., a Delaware corporation having a place of business at 200 Cambridge park Drive, Suite 3100 (hereinafter "Assignor"), has transferred the entire right, title and interest in and to the inventions disclosed in the Application(s) listed in **Appendix I**, and in and to all embodiments of the inventions, heretofore conceived, made or discovered (collectively hereinafter referred to as "Inventions") entitled as listed in **Appendix I** and having serial numbers and filing dates with the United States Patent and Trademark Office also listed in **Appendix I**.

WHEREAS, Sotio, LLC, a Delaware limited liability company having a place of business at 180 Canal Street, Suite 300, Boston, MA 02114, (hereinafter "Assignee"), has acquired the entire right, title and interest in and to said Inventions, and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

Said Assignor has hereby sold, assigned, transferred and conveyed unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

Said Assignor has hereby agreed to reasonably cooperate with said Assignee to enable said Assignee to effect the transfer of the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such reasonable cooperation by the Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed reasonably necessary by the parties (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions.

The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor, its successors, assigns and other legal representatives.

Said Assignor hereby warrants and represents, as of the date first written above, that said Assignor has not entered into any assignment, contract, or understanding in conflict herewith.

Said Assignor hereby requests that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

Said Assignor hereby authorizes and requests McDermott Will & Emery LLP to supply any missing patent/application identification information or correct any errors in the patent/application identification information provided above, whether discovered prior to or after recordation.

This instrument will be interpreted and construed in accordance with the laws of Delaware without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

CORPORATE TO CORPORATE ASSIGNMENT

Attorney Docket No.: _____

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below.

Date: September 21, 2020

ASSIGNOR

By: 

Name: Charles Wilson, Ph.D.

Title: Chief Executive Officer

RECEIVED AND AGREED TO BY ASSIGNEE:

Date: 21 SEP 2020

By: 

Name: Matthew Plaud, MSM

Title: Chief Executive Officer

Appendix I

Serial Number	Title	Filing Date	Attorney Docket No.
PCT/US2019/060287	ANTI-GPC3 CHIMERIC ANTIGEN RECEPTORS (CARs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF	November 7, 2019	112309-0013-70010WO00
USSN 62/756,683	ANTI-GPC3 CHIMERIC ANTIGEN RECEPTORS (CARs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF	November 7, 2018	112309-0012-70010US00
PCT/US2019/040346	CHIMERIC RECEPTORS IN COMBINATION WITH TRANS METABOLISM MOLECULES ENHANCING GLUCOSE IMPORT AND THERAPEUTIC USES THEREOF	July 2, 2019	112309-0016-70011WO00
USSN 62/693,668	ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS METABOLISM MOLECULES ENHANCING GLUCOSE IMPORT AND THERAPEUTIC USES THEREOF	July 3, 2018	112309-0014-70011US00
USSN 62/693,677	CHIMERIC ANTIGEN RECEPTORS (CARs) IN COMBINATION WITH TRANS METABOLISM MOLECULES ENHANCING GLUCOSE IMPORT AND THERAPEUTIC USES THEREOF	July 3, 2018	112309-0029-70018US00
USSN 62/713,369	CHIMERIC ANTIGEN RECEPTORS (CARs) IN COMBINATION WITH TRANS METABOLISM MOLECULES ENHANCING GLUCOSE IMPORT AND THERAPEUTIC USES THEREOF	August 1, 2018	112309-0030-70018US01
USSN 62/756,664	ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS METABOLISM MOLECULES ENHANCING	November 7, 2018	112309-0015-70011US01

	GLUCOSE IMPORT AND THERAPEUTIC USES THEREOF		
USSN 62/756,698	CHIMERIC ANTIGEN RECEPTORS (CARs) IN COMBINATION WITH TRANS METABOLISM MOLECULES ENHANCING GLUCOSE IMPORT AND THERAPEUTIC USES THEREOF	November 7, 2018	112309-0031-70018US02
PCT/US2019/050013	CHIMERIC RECEPTOR POLYPEPTIDES IN COMBINATION WITH TRANS METABOLISM MOLECULES MODULATING INTRACELLULAR LACTATE CONCENTRATIONS AND THERAPEUTIC USES THEREOF	September 6, 2019	112309-0022-70014WO00
USSN 62/728,306	ANTIBODY-COUPLED T CELL RECEPTORS IN COMBINATION WITH TRANS METABOLISM MOLECULES MODULATING INTRACELLULAR LACTATE CONCENTRATIONS AND THERAPEUTIC USES THEREOF	September 7, 2018	112309-0021-70014US00
USSN 62/728,338	CHIMERIC ANTIGEN RECEPTORS IN COMBINATION WITH TRANS METABOLISM MOLECULES MODULATING INTRACELLULAR LACTATE CONCENTRATIONS AND THERAPEUTIC USES THEREOF	September 7, 2018	112309-0034-70021US00
PCT/US2019/046550	CHIMERIC ANTIGEN RECEPTOR POLYPEPTIDES IN COMBINATION WITH TRANS METABOLISM MOLECULES MODULATING KREBS CYCLE AND THERAPEUTIC USES THEREOF	August 14, 2019	112309-0024-70015WO00
USSN 62/718,491	ANTIBODY-COUPLED T CELL RECEPTORS (ACTRS) IN COMBINATION WITH TRANS METABOLISM MOLECULES MODULATING KREBS CYCLE AND THERAPEUTIC USES THEREOF	August 14, 2018	112309-0023-70015US00

USSN 62/718,579	CHIMERIC ANTIGEN RECEPTORS (CARs) IN COMBINATION WITH TRANS METABOLISM MOLECULES MODULATING KREBS CYCLE AND THERAPEUTIC USES THEREOF	August 14, 2018	112309-0035-70022US00
-----------------	--	-----------------	-----------------------

PATENT

REEL: 058661 FRAME: 0041

RECORDED: 01/14/2022